Abstract
Background: Omalizumab is effective in the treatment of severe persistent allergic asthma that is not controlled with long-acting beta-agonists/ high-dose inhaled corticosteroids.
Objective: To conduct a systematic exploratory review and meta-analysis of studies with omalizumab in Latin America.
Methods: A search of real-life studies on the effectiveness of omalizumab in asthma control conducted in Latin America was carried out.
The average of the aggregate effectiveness of omalizumab in asthma control (Pooled Analysis) was estimated by using a random effects model.
Results: Nine open uncontrolled observational studies were identified; these studies included a total of 1 118 patients with severe uncontrolled asthma. The average of the estimated aggregate effectiveness of omalizumab in the good control of severe asthma was of 80.6 % in children and 78.9 % in adults.
Conclusions: The average of the estimated aggregate effectiveness of omalizumab in the control of severe asthma in both children and adults in Latin America was over 78 %. Randomized controlled studies are required in order to establish the efficacy and effectiveness of omalizumab in the control of severe asthma and in the different subgroups by level of eosinophils.
References
Ocampo J, Gaviria R, Sánchez J. Prevalence of asthma in Latin America. Critical look at ISAAC and other studies. Rev Alerg Mex. 2017;64(2):188-197. DOI: 10.29262/ram.v64i2.256
Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005;17(3)191-197. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/8111/a07v17n3.pdf?sequence=1&isAllowed=y
Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4(1):120-129. DOI: 10.1016/j.jaip.2015.08.003
Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53:1901046. DOI: 10.1183/13993003.01046-2019
Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23-32. DOI: 10.1080/03007995.2019.1660539
Serpa FS, Piana MP, Braga Neto F, Campinhos FL, Silveira MG da, Chiabai J, et al. Effectiveness of anti-IgE therapy for asthma control. Braz J Allergy Immunol. 2014;2(4):147-153.
Rodrigues AM, Roncada C, Santos G, Heinzmann-Filho JP, de Souza RG, Vargas MHM, et al. Características clínicas de crianças e adolescentes Brasileiros com asma grave resistente a terapia. J Bras Pneumol. 2015;41(4):343-350. DOI: 10.1590/S1806-37132015000004462
De Carvalho-Pinto RM, Agondi RC, Giavina-Bianchi P, Cukier A, Stelmach R. Omalizumabe em pacientes com asma grave não controlada: critérios de elegibilidade bem definidos para promover o controle da asma. J Bras Pneumol. 2017;43(6):487-489. DOI: 10.1590/S1806-37562017000000012
Giubergia V, Ramírez-Farías MJ, Pérez V, Crespi N, Castaños C. Impacto clínico del tratamiento con omalizumab en niños con asma grave. Reporte de una experiencia local. Arch Argent Pediatr. 2019;117(2):e115-e120. Disponible en: https://www.sap.org.ar/uploads/archivos/general/files_ae_giubergia_25-2pdf_1550168734.pdf
Bergna M, Braunstahl GJ, Canvin J, Peachey G, Chen CW, Georgiou P, et al. Impacto del tratamiento con omalizumab sobre los costos indirectos y la utilización de recursos en pacientes con asma alérgica. Argentina: Asociación Argentina de Medicina Respiratoria; 2012.
Herrera AM, Hernández J, Perillán JA, Lezana V, Álvarez C, Marinovic MA, et al. Omalizumab treatment on severe asthma patients: pediatric experience in Chile and literature review. Rev Chil Enferm Respir. 2016;32(3)160-168. DOI: 10.4067/S0717-73482016000300004
Morales-Múnera O, Pedraza Á, Niño-Serna L. Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia. Rev Alerg Mex. 2018;65(3):142-152. DOI: 10.29262/ram.v65i3.510
Vargas-Correa JB, Bracamonte-Peraza R, Espinosa-Morales SM, Vázquez-Nava F. Clinical experience with omalizumab in patients with severe asthma. Real-world data. Rev Alerg Mex. 2016;63(3):216-226. DOI: 10.29262/ram.v63i3.144
Herrera-García J. Omalizumab en el tratamiento del asma moderada a grave persistente en el contexto de asma alérgica y no alérgica. Med Int Mex. 2015;31(6):693-700. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2015/mim156g.pdf
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. DOI: 10.1002/14651858.CD003559.pub4
Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1-342. DOI: 10.3310/hta17520
Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156-164. DOI: 10.1016/j.jaip.2018.04.043
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México